Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN). Let's consider why these three biotechs are solid buys for the next decade.
In the latest trading session, Amgen (AMGN) closed at $225.99, marking a -0.39% move from the previous day.
Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.